LSI Europe

Excited to share insights from the riveting panel discussion on neuromodulation at the LSI Europe '24 Emerging Medtech Summit in Sintra, Portugal! It was an honor to represent CereGate alongside a stellar group of co-panelists: 🧠 Ana Maiques, CEO of Neuroelectrics  💼 Catherine Poulin-Filion, Sectoral Asset Management 🚀 Meron Gribetz, Inner Cosmos 💸 Melissa Lezameta, Epidarex Capital In this engaging discussion, we dove deep into: ✅ The current state and future potential of neuromodulation technologies like brain-computer interfaces (BCIs)  ✅ Ethical considerations surrounding invasive approaches ✅ Societal reactions and implications of these cutting-edge advancements Some key takeaways: 📌 Neuromodulation is a resilient and rapidly evolving field with immense potential for personalized therapies 📌 Advancements in AI, closed-loop systems, and minimally invasive techniques are driving innovation  📌 Collaboration across startups will be crucial to realize the full impact of neurotech 📌 Proactively addressing privacy concerns and engaging in public discourse is essential as the technology progresses Check out the full panel discussion here: https://lnkd.in/d7tu9kkQ I'm truly excited about the future of neuromodulation and its capacity to revolutionize patient care. Let's keep the conversation going! #neuromodulation #medtech #BCI #LSI #CereGate #braininterfacethefuture #CBI #LSI2024

Noze is enabling early disease diagnostics through digital odor perception. The company has developed a cutting-edge digital nose capable of detecting and identifying odors with precision in real-world settings. By identifying breath-based odor biomarkers, Noze aims to deliver real-time, non-invasive disease detection at the point of care. Leveraging exclusive licenses to NASA-patented technology, Noze combines advanced sensors with AI to replicate the human olfactory system. This innovation enables the detection of volatile organic compounds (VOCs) in exhaled breath, paving the way for breakthroughs in disease screening and diagnostics. Want to learn more about Noze? Catch Karim Aly’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

The 2025 event calendar is set — Three events, three countries, and a world of possibilities. Join us in three iconic cities across three countries for a year filled with innovation and opportunity: LSI USA '25 (Dana Point) March 17th - 21st, 2025 At the Waldorf Astoria Monarch Beach Resort LSI Asia '25 (Singapore) June 10th - 13th, 2025 At The Ritz-Carlton® Millenia Singapore LSI Europe '25 (London) September 7th - 11th, 2025 At the JW Marriott Grosvenor House London If you plan on joining us next year, now is the perfect time to lock in our end-of-year rates for events and hotels. You can register today on our website or reach out to our team today. We look forward to seeing you in 2025!

As we continue to spread the word about the global health threat of resistance to antibiotics during this World Health Organization #AntimicrobialResistance #AwarenessWeek, we are pleased to share that our video from #LSIEurope24 is now available. Find an excerpt on the topic below and watch the rest of our CEO's 9-minute presentation to hear how we plan to advance infection prevention in surgical implants. https://lnkd.in/d-K7ddFW #awareness #top10 #globalhealthcarechallenges #infectionprotection #hylomorph #healthcare #medtech #healthcareinnovation

Ebenbuild, a Munich-based startup, is revolutionizing the treatment of acute respiratory distress syndrome (ARDS) through AI and physics. The company's proprietary software creates digital twin models of patients' lungs using computer tomography and AI. These models enable personalized and precise mechanical ventilation, helping physicians manage lung stress and reduce complications. Traditional methods rely on patient body weight, often leading to suboptimal results. Ebenbuild’s approach considers individual lung physiology, predicting harmful ventilation settings and allowing safer, customized adjustments. This innovation reduces the frequency of ventilator adjustments, saving time, and costs, and ultimately shortening the duration of artificial ventilation. Beyond ventilation, Ebenbuild is expanding its technology to drug research, aiming to optimize drug efficacy in lung treatment. By predicting how drugs will affect specific lung areas, the technology could enhance clinical trials, reduce costs, and improve patient outcomes. Want to learn more about Ebenbuild? Catch Kei Wieland Müller’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Last week Osteal Therapeutics announced positive 12-month results from their APEX clinical trials, evaluating VT-X7 KIT for treating periprosthetic joint infections (PJI) of the hip and knee. Their VT-X7 KIT demonstrated a higher success rate (71%) compared to the standard two-stage approach (52%) for treating periprosthetic joint infections (PJI) of the hip and knee. Patients treated with VT-X7 underwent revision surgery significantly faster, with a median time of just 7 days versus 98 days for standard treatment. Additionally, the VT-X7 approach reduced procedure duration by 62 minutes and lowered the overall burden of PJI by 71%, offering a more efficient and patient-friendly solution for these challenging infections. Want to learn more about Osteal Therapeutics? Catch David Thompson’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Earlier this week Qaelon Medical announced the completion of prototype development for the world’s first and only surgical leak detection platform. The latest-generation prototype detects leaks as small as 1 mm—smaller than a surgical staple—in just 30 seconds, setting a new benchmark for surgical safety. Qaelon's patented technology replaces traditional visual testing with a standardized, data-driven approach. Utilizing digital sensors and proprietary software, the platform employs advanced algorithms to identify leaks that other methods often miss. This rapid detection, typically within a minute, allows surgical teams to act immediately, potentially saving lives and reducing the $1.1 billion annual cost of managing surgical leaks in the U.S. Want to learn more about Qaelon Medical? Catch Liam J. Burns’s full studio interview from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

📽️ (Re)discover the speech given by Sebastien Ladet, CEO of Affluent Medical, at #LSIEurope24. Last September, Affluent Medical travelled to Sintra, Portugal, to take part in LSI Europe 24! It was an exceptional event that gave our teams the opportunity to talk to leading investors and world leaders in medical technology and healthcare. On this occasion, our CEO Sébastien Ladet took to the stage to give a detailed presentation of Affluent Medical's innovative solutions: biomimetic, minimally invasive and adjustable devices 💡🫀 It was also an opportunity to look back at Affluent Medical's ambition and the latest advances that have recently marked the company's history!  💬 « 𝘛𝘸𝘰 𝘺𝘦𝘢𝘳𝘴 𝘢𝘨𝘰, 𝘸𝘩𝘦𝘯 𝘐 𝘫𝘶𝘮𝘱𝘦𝘥 𝘰𝘧𝘧 𝘮𝘺 𝘫𝘰𝘣 𝘢𝘯𝘥 𝘮𝘰𝘷𝘦𝘥 𝘣𝘢𝘤𝘬 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘶𝘴 𝘵𝘰 𝘍𝘳𝘢𝘯𝘤𝘦, 𝘪𝘵 𝘸𝘢𝘴 𝘳𝘦𝘢𝘭𝘭𝘺 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘦 𝘦𝘹𝘤𝘪𝘵𝘦𝘮𝘦𝘯𝘵 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘦 𝘬𝘦𝘺 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵𝘪𝘢𝘵𝘦𝘥 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘵𝘩𝘢𝘵 𝘈𝘧𝘧𝘭𝘶𝘦𝘯𝘵 𝘸𝘢𝘴 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘪𝘯𝘨. 𝘛𝘩𝘪𝘴 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘴 𝘴𝘦𝘷𝘦𝘳𝘢𝘭 𝘺𝘦𝘢𝘳𝘴 𝘰𝘧 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 𝘴𝘶𝘳𝘨𝘦𝘰𝘯𝘴, 𝘱𝘩𝘺𝘴𝘪𝘤𝘪𝘢𝘯𝘴, 𝘢𝘯𝘥 𝘦𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘴, 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘸𝘩𝘪𝘤𝘩 𝘸𝘦 𝘣𝘶𝘪𝘭𝘵 𝘵𝘩𝘪𝘴 𝘱𝘰𝘳𝘵𝘧𝘰𝘭𝘪𝘰 𝘰𝘧 𝘵𝘩𝘳𝘦𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴, 𝘵𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘢 $10 𝘣𝘪𝘭𝘭𝘪𝘰𝘯 𝘮𝘢𝘳𝘬𝘦𝘵 𝘸𝘪𝘵𝘩 𝘥𝘰𝘶𝘣𝘭𝘦-𝘥𝘪𝘨𝘪𝘵 𝘨𝘳𝘰𝘸𝘵𝘩" ▶️ Press Play and discover an extract from his speech 👇

Xeltis recently announced that the FDA's Center for Devices and Radiological Health (CDRH) has granted Breakthrough Device Designation to aXess™, its innovative vascular access graft. Designed for patients requiring hemodialysis, aXess™ enables the creation of a permanent, living vessel by leveraging Xeltis’ proprietary Endogenous Tissue Restoration (ETR) platform. This transformative approach addresses the limitations of current options, offering hope for millions of individuals needing vascular access or cardiovascular replacements annually. Want to learn more about Xeltis? Catch Eliane Schutte’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

Shela Health is a women's health startup redefining prenatal care through early prediction and precision recommendations for pregnancy complications. The company leverages cutting-edge AI models and multiomics—integrating genomics, proteomics, metabolomics, and microbiome data—to identify risks as early as the 12th week of pregnancy. This enables tailored interventions to prevent conditions like preeclampsia, preterm birth, and gestational diabetes. With a mission to transition women's healthcare from reactive to proactive, Shela Health provides expectant mothers with accurate risk assessments and personalized care plans. Their innovative platform combines clinical insights with biological data, empowering healthcare providers to enhance maternal and fetal outcomes. Want to learn more about Shela Health? Catch Sharon Handelman-Gotlib’s full video presentation from LSI Europe ‘24 on our website and YouTube channel. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.